Lexington, MA December 11, 2008 - Protein Forest™, a leading developer of state-of-the-art sample fractionation technology and bioinformatics software for protein research, today announced that Children’s Hospital Boston has recently installed the digital ProteomeChip™ System (dPC™) to use in a recently NIH funded study entitled “Multi-disciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network (U01) Discovery Site”.
This study will be carried out in the laboratories of Keith Solomon, PhD., Assistant Professor of Orthopedic Surgery at Harvard Medical School and Administrative Director of the Proteomics Center at Children’s Hospital Boston, Richard Lee, MD, Assistant Professor of Surgery (HMS), Marsha Moses, Professor of Surgery (HMS), and Director of the Vascular Biology Program (CHB), and the Proteomics Center at Children’s Hospital Boston, under the direction of Hanno Steen, Ph.D., Assistant Professor of Pathology and Systems Biology (HMS).
Dr. Solomon’s lab had been evaluating technologies to discover new biomarkers in urine and has selected the dPC system for this study. The ability to identify new potential biomarkers never before seen with other methods, the greater reproducibility, faster analysis and the ease of use were critical factors in selecting the dPC platform for this study.
The ProteomeChip system fractionates and concentrates proteins or peptides by parallel isoelectric focusing in 30 minutes for superior mass spec analysis. Additionally, pI information from the dPC prefractionation enables rapid discovery of post-translational modification based biomarkers.
“We are proud to work with Protein Forest.” said Keith Solomon, Ph.D., Assistant Professor of Orthopedic Surgery at Harvard Medical School and Administrative Director of the Proteomics Center at Children’s Hospital Boston. The ability to analyze complex proteomes has been made simpler by the powerful tools that Protein Forest has created. We anticipate that the dPC technology and MSRAT software will speed discovery time resulting in identification of potential biomarkers at 1/3 of the time required by standard technologies.”
“We are pleased that this leading research team, from Harvard Medical School, has been selected as the premier NIH Discovery Site to identify proteomic markers for Chronic Pelvic Pain” said Russell Garlick, Ph.D., President and CEO of Protein Forest. “This NIH funding reflects the growing confidence by the medical research field to apply mass spec based proteomics and the digital ProteomeChip technology to clinical research.”
About Protein Forest, Inc.
Protein Forest, Inc., a privately held company located in Lexington, Massachusetts, is a leading developer and manufacturer of state-of-the-art sample fractionation technology and bioinformatics software for mass spectrometry. The company develops, manufactures, and markets instruments, consumables, and bioinformatics software products for scientists in the life science, drug discovery, pharmaceutical, biotech, and diagnostic industries around the world. For more information, visit www.proteinforest.com.